[{"id":"dc0579d6-d285-4c4f-a4da-1f44bfe4d346","acronym":"","url":"https://clinicaltrials.gov/study/NCT06069024","created_at":"2023-10-05T16:11:22.043Z","updated_at":"2024-07-02T16:35:10.669Z","phase":"","brief_title":"Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide","source_id_and_acronym":"NCT06069024","lead_sponsor":"Qianfoshan Hospital","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2024-04-09"},{"id":"2fd1f36d-538c-4925-82be-67b0b08c4340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04301076","created_at":"2021-01-18T20:51:47.723Z","updated_at":"2024-07-02T16:35:16.189Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATL)","source_id_and_acronym":"NCT04301076","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • CD2","pipe":"","alterations":" ","tags":["CD4 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-06"},{"id":"df710e35-6fee-433d-8b5e-2a0f0b481289","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846880","created_at":"2023-05-06T14:04:17.467Z","updated_at":"2024-07-02T16:35:19.162Z","phase":"Phase 1","brief_title":"VitD3 Supplementation in Patients With Multiple Myeloma","source_id_and_acronym":"NCT05846880","lead_sponsor":"Amany Keruakous, MD, MS.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-02-15"},{"id":"92d236cb-41f3-4477-91bc-450b492b95a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01054196","created_at":"2021-01-18T04:08:59.899Z","updated_at":"2025-02-25T14:31:39.955Z","phase":"Phase 1/2","brief_title":"Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study","source_id_and_acronym":"NCT01054196","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-01"},{"id":"bf2c24bb-0980-48a4-95ed-efc1d3846155","acronym":"","url":"https://clinicaltrials.gov/study/NCT02561273","created_at":"2021-01-18T12:24:07.010Z","updated_at":"2024-07-02T16:35:26.335Z","phase":"Phase 1/2","brief_title":"Combination Chemotherapy \u0026 Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT02561273","lead_sponsor":"University of Nebraska","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2023-12-13"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"52f8a9a1-95f2-46c1-9a42-1380744675d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02126553","created_at":"2021-01-18T09:51:35.162Z","updated_at":"2024-07-02T16:36:00.548Z","phase":"Phase 2","brief_title":"Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission","source_id_and_acronym":"NCT02126553","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/13/2014","start_date":" 11/13/2014","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2022-11-11"},{"id":"3a0c49c1-727b-492b-bc54-7034bb716618","acronym":"KMM1911","url":"https://clinicaltrials.gov/study/NCT05497102","created_at":"2022-08-15T11:10:45.029Z","updated_at":"2024-07-02T16:36:05.577Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","source_id_and_acronym":"NCT05497102 - KMM1911","lead_sponsor":"Samsung Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-08-12"},{"id":"019e5c1f-7cc6-4bf5-9b54-11b80b290251","acronym":"","url":"https://clinicaltrials.gov/study/NCT03375567","created_at":"2021-01-29T07:16:40.130Z","updated_at":"2024-07-02T16:36:16.671Z","phase":"","brief_title":"Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone","source_id_and_acronym":"NCT03375567","lead_sponsor":"Yale University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2022-02-24"},{"id":"d20a1a1c-6571-4f80-9551-ee94421c97f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01057121","created_at":"2021-01-29T07:00:24.457Z","updated_at":"2024-07-02T16:36:17.455Z","phase":"Phase 1/2","brief_title":"Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma","source_id_and_acronym":"NCT01057121","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/27/2010","start_date":" 08/27/2010","primary_txt":" Primary completion: 08/04/2014","primary_completion_date":" 08/04/2014","study_txt":" Completion: 08/04/2014","study_completion_date":" 08/04/2014","last_update_posted":"2022-02-08"},{"id":"4ce7a3df-8c27-474f-af59-9ed067c83069","acronym":"","url":"https://clinicaltrials.gov/study/NCT01556776","created_at":"2021-01-18T06:35:30.682Z","updated_at":"2025-02-25T14:33:24.033Z","phase":"Phase 3","brief_title":"A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy","source_id_and_acronym":"NCT01556776","lead_sponsor":"German CLL Study Group","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 07/20/2012","start_date":" 07/20/2012","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 01/14/2021","study_completion_date":" 01/14/2021","last_update_posted":"2022-01-05"},{"id":"775c2a76-908f-4588-90eb-00f72be8acce","acronym":"STAMINA","url":"https://clinicaltrials.gov/study/NCT01109004","created_at":"2021-01-18T04:23:28.887Z","updated_at":"2024-07-02T16:36:19.703Z","phase":"Phase 3","brief_title":"Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)","source_id_and_acronym":"NCT01109004 - STAMINA","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 758","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 01/15/2017","primary_completion_date":" 01/15/2017","study_txt":" Completion: 03/03/2018","study_completion_date":" 03/03/2018","last_update_posted":"2021-12-09"},{"id":"b3557694-13d2-410d-9e56-588a1d4c4b25","acronym":"","url":"https://clinicaltrials.gov/study/NCT05105412","created_at":"2021-11-03T12:53:04.761Z","updated_at":"2024-07-02T16:36:21.539Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas","source_id_and_acronym":"NCT05105412","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • lenalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 10/31/2021","start_date":" 10/31/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2021-11-03"},{"id":"f60e6b64-d4a6-4c87-b498-d69b76e6150f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01402284","created_at":"2021-01-18T05:45:42.710Z","updated_at":"2025-02-25T14:32:59.232Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","source_id_and_acronym":"NCT01402284","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 07/21/2011","start_date":" 07/21/2011","primary_txt":" Primary completion: 07/10/2016","primary_completion_date":" 07/10/2016","study_txt":" Completion: 09/24/2020","study_completion_date":" 09/24/2020","last_update_posted":"2021-03-02"},{"id":"8e9f015e-2f49-43b1-ac27-09c787f2c5c6","acronym":"AZALENA","url":"https://clinicaltrials.gov/study/NCT02472691","created_at":"2021-01-18T11:54:11.739Z","updated_at":"2025-02-25T14:35:40.382Z","phase":"Phase 2","brief_title":"Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT","source_id_and_acronym":"NCT02472691 - AZALENA","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" FLT3 • ASXL1 • TET2 • WT1","pipe":" | ","alterations":" FLT3 mutation • ASXL1 mutation • TET2 mutation","tags":["FLT3 • ASXL1 • TET2 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • ASXL1 mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/23/2020","primary_completion_date":" 04/23/2020","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2020-05-28"},{"id":"fa0548a3-d407-4439-bafc-3c6f27298643","acronym":"","url":"https://clinicaltrials.gov/study/NCT04326296","created_at":"2021-01-18T20:57:23.934Z","updated_at":"2024-07-02T16:36:44.999Z","phase":"Phase 1","brief_title":"The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer","source_id_and_acronym":"NCT04326296","lead_sponsor":"LiNing","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/30/2020","start_date":" 05/30/2020","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2020-05-15"},{"id":"ed6ae788-f12f-4a38-a73d-cfa2405c9257","acronym":"","url":"https://clinicaltrials.gov/study/NCT01647165","created_at":"2021-01-29T07:03:28.608Z","updated_at":"2025-02-25T14:56:29.350Z","phase":"Phase 2","brief_title":"Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance","source_id_and_acronym":"NCT01647165","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • dexamethasone"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/11/2012","start_date":" 07/11/2012","primary_txt":" Primary completion: 06/26/2015","primary_completion_date":" 06/26/2015","study_txt":" Completion: 06/26/2015","study_completion_date":" 06/26/2015","last_update_posted":"2019-12-12"},{"id":"d744a8f1-5bc3-4ece-a008-41f2a56e21fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01142232","created_at":"2021-01-18T04:32:35.452Z","updated_at":"2025-02-25T14:32:05.045Z","phase":"Phase 1/2","brief_title":"Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma","source_id_and_acronym":"NCT01142232","lead_sponsor":"Attaya Suvannasankha","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 08/27/2010","start_date":" 08/27/2010","primary_txt":" Primary completion: 11/06/2015","primary_completion_date":" 11/06/2015","study_txt":" Completion: 05/18/2019","study_completion_date":" 05/18/2019","last_update_posted":"2019-10-22"},{"id":"d8424f36-d614-46d5-bad3-44cf844d290f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00829647","created_at":"2021-01-18T03:09:26.471Z","updated_at":"2025-02-25T14:30:38.465Z","phase":"Phase 1/2","brief_title":"A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00829647","lead_sponsor":"Scripps Health","biomarkers":" CD38","pipe":" | ","alterations":" Chr del(11q)","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • lenalidomide • Campath (alemtuzumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2019-04-11"},{"id":"6e6a1a07-13b7-4a06-9bdd-3d7cfd8ddfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00553644","created_at":"2021-01-18T02:01:01.760Z","updated_at":"2024-07-02T16:37:05.730Z","phase":"Phase 2","brief_title":"Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT00553644","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCND1 • CD4 • CD5 • FCER2","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 11/15/2007","start_date":" 11/15/2007","primary_txt":" Primary completion: 12/31/2012","primary_completion_date":" 12/31/2012","study_txt":" Completion: 01/21/2014","study_completion_date":" 01/21/2014","last_update_posted":"2018-10-30"},{"id":"7145fa5e-0111-4f5b-9661-7b4fb6f2cf31","acronym":"REMMYDYS","url":"https://clinicaltrials.gov/study/NCT00744536","created_at":"2021-01-18T02:48:47.458Z","updated_at":"2025-02-25T14:26:16.015Z","phase":"Phase 2","brief_title":"Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS","source_id_and_acronym":"NCT00744536 - REMMYDYS","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 01/01/2012","primary_completion_date":" 01/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2017-06-09"},{"id":"38b81154-a874-4679-9d6c-6b3478c553e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01011894","created_at":"2021-01-18T03:57:45.691Z","updated_at":"2025-02-25T14:31:29.365Z","phase":"Phase 2","brief_title":"Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age","source_id_and_acronym":"NCT01011894","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD5 • FCER2","pipe":"","alterations":" ","tags":["CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 11/06/2009","start_date":" 11/06/2009","primary_txt":" Primary completion: 02/23/2016","primary_completion_date":" 02/23/2016","study_txt":" Completion: 02/23/2016","study_completion_date":" 02/23/2016","last_update_posted":"2017-05-18"},{"id":"1b940136-1411-4455-9d96-af20cf1be948","acronym":"","url":"https://clinicaltrials.gov/study/NCT00899080","created_at":"2021-01-18T03:27:19.009Z","updated_at":"2024-07-02T16:37:22.051Z","phase":"","brief_title":"Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide","source_id_and_acronym":"NCT00899080","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CTSG","pipe":"","alterations":" ","tags":["CTSG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/04/2008","start_date":" 07/04/2008","primary_txt":" Primary completion: 08/04/2008","primary_completion_date":" 08/04/2008","study_txt":" Completion: 08/04/2008","study_completion_date":" 08/04/2008","last_update_posted":"2017-05-17"},{"id":"67592ff1-2eef-41c1-bb33-147db74c0221","acronym":"","url":"https://clinicaltrials.gov/study/NCT01003821","created_at":"2021-01-18T03:55:27.706Z","updated_at":"2025-02-25T14:31:25.818Z","phase":"","brief_title":"Lenalidomide as a Chemopreventive Agent for High-Risk Early Stage B-cell Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT01003821","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IGH","pipe":" | ","alterations":" IGH mutation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2016-06-30"}]